AIM ImmunoTech CEO and President Thomas K Equels bought 5,900 shares at $0.22 per share, leaving him with 69,822 shares. The purchase represents about 8.5% of his resulting shareholding, giving investors a disclosed measure of the transaction’s size within his AIM ImmunoTech position.

Key Highlights

  • The transaction carried code P, identifying it as an open-market purchase.
  • The purchase represented about 8.5% of Equels’ resulting shareholding.
  • Thomas K Equels is AIM ImmunoTech’s CEO and President.

AIM ImmunoTech Inc. (AMEX: AIM) CEO and President Thomas K Equels bought 5,900 shares at $0.22 per share. His reported holding after the purchase was 69,822 shares.

CEO Purchase Classified as Open-Market Transaction

The purchase took place on 14 September 2026 and carried transaction code P, which identifies an open-market purchase. Equels serves as AIM ImmunoTech’s CEO and President. The transaction represented about 8.5% of his resulting shareholding.